In a patient with heart failure with mildly reduced ejection fraction and a resting heart rate of 69 bpm, should a beta‑blocker be started?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Should Beta-Blocker Be Started in HFmrEF with HR 69?

Yes, beta-blocker therapy should be started in this patient with heart failure with mildly reduced ejection fraction (HFmrEF), as the evidence supports mortality and morbidity benefits in this population, and a heart rate of 69 bpm is not a contraindication.

Rationale for Beta-Blocker Initiation

The 2022 AHA/ACC/HFSA guidelines provide a Class 2b recommendation for beta-blockers in HFmrEF 1, which represents a weaker recommendation than for HFrEF but still supports their use. While this is not as strong as the Class 1 recommendation for HFrEF (EF ≤40%), the evidence base demonstrates meaningful benefits.

Evidence Supporting Beta-Blocker Use in HFmrEF

The most compelling recent evidence comes from an individual patient-level meta-analysis of 11 double-blind randomized trials 2. For patients with LVEF 40-49%, beta-blockers reduced:

  • All-cause mortality: 7.2% vs 12.4% with placebo (adjusted HR 0.59,95% CI 0.34-1.03)
  • Cardiovascular death: 4.5% vs 9.2% with placebo (adjusted HR 0.48,95% CI 0.24-0.97)

This represents approximately a 40% reduction in mortality risk, which is clinically meaningful even if the confidence interval crosses 1.0 for all-cause mortality.

A 2023 real-world analysis from the PINNACLE Registry 3 involving 75,674 patients with HFmrEF showed that beta-blockers were associated with decreased risk of both HF hospitalization and death in HFmrEF patients. Importantly, this benefit diminished as EF increased above 50%, with potential harm when EF exceeded 60%.

Heart Rate Considerations

Your patient's heart rate of 69 bpm is NOT a contraindication to beta-blocker initiation. The guidelines specify that symptomatic bradycardia is a contraindication 4, not a specific heart rate threshold.

Key points about heart rate:

  • Beta-blockers typically reduce heart rate by approximately 12 beats/min 5
  • The benefit of beta-blockers in patients with sinus rhythm occurs regardless of baseline heart rate (interaction p = 0.35) 5
  • Bradycardia becomes a concern only when symptomatic or when it requires discontinuation of rate-lowering medications 4

Practical Implementation

Follow this stepwise approach 4, 6:

  1. Ensure patient stability: Patient should be relatively stable without marked fluid retention or need for IV inotropes
  2. Confirm background therapy: Patient should be on ACE inhibitor/ARB/ARNI unless contraindicated
  3. Start low, go slow: Use evidence-based beta-blockers only:
    • Bisoprolol: Start 1.25 mg daily, target 10 mg daily
    • Carvedilol: Start 3.125 mg twice daily, target 25-50 mg twice daily
    • Metoprolol succinate (extended-release): Start 12.5-25 mg daily, target 200 mg daily
  4. Titration schedule: Double dose every 1-2 weeks if tolerated 4, 6
  5. Monitoring: Check blood pressure and heart rate at each titration; assess for worsening symptoms

Common Pitfalls to Avoid

  • Don't use non-evidence-based beta-blockers: Only bisoprolol, carvedilol, and metoprolol succinate have proven mortality benefit 6, 7
  • Don't withhold due to asymptomatic bradycardia: A resting HR of 69 is acceptable for initiation
  • Don't stop abruptly if side effects occur: First optimize diuretics or reduce vasodilators; temporarily reduce beta-blocker dose if necessary, but always attempt reintroduction 4
  • Don't delay initiation: The survival benefit includes reduction in sudden death 7, so treatment should not be postponed in stable patients

Contraindications to Check

Absolute contraindications 4:

  • Asthma bronchiale or severe bronchial disease
  • Symptomatic bradycardia or hypotension (not just numbers)
  • Decompensated heart failure requiring IV inotropes

Relative contraindications requiring specialist referral 4:

  • Severe heart failure (NYHA Class III/IV)
  • Previous beta-blocker discontinuation due to symptoms
  • Intolerance to low doses

Special Considerations for HFmrEF

HFmrEF represents a transitional phenotype—many patients either improved from lower EF or deteriorated from higher EF 8. Continue beta-blocker therapy even if EF improves above 40% 1, as these patients benefit from ongoing neurohormonal blockade. The evidence suggests beta-blockers provide the most robust benefit when EF is below 50% 3, making your patient with mildly reduced EF an ideal candidate.

The 2020 ACC/AHA performance measures emphasize that beta-blocker therapy should be prescribed to all eligible patients with current or prior LVEF ≤40% 6, and the evidence extends this benefit into the 40-49% range 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.